Despite the known selectivity of the TGF-β1 isoform linked to cancer, the vast majority of TGF-β blockade therapeutics to date indiscriminately target all TGF-β isoforms, an effect likely to contribute to the adverse effects of such therapies given the indispensable role of the other isoforms in normal tissues. Here, TGFB1 is linked to cancer.